Health Economic Evaluations (HEEs) play a crucial role in reimbursement decisions, particularly in the realm of healthcare technologies. However, these evaluations are often fraught with uncertainty, posing significant challenges to decision-makers. The assessment of uncertainty is a cornerstone of these evaluations, helping to gauge the robustness of results and the potential consequences of uncertainty related to decisions. Yet, there is currently no comprehensive overview of the methods used for uncertainty assessment in HEEs.
A recent review aimed to fill this gap, exploring the various methods used for uncertainty assessment in model-based HEEs. The review identified a total of 80 different methods for assessing uncertainty: 30 for identification, 28 for analysis, and 22 for communication. These methods cater to different sources of uncertainty, with most identification methods developed to assess related concepts like validity, model quality, and relevance.
This review aids analysts and decision-makers by guiding them to choose suitable uncertainty assessment techniques based on their specific needs and the overall assessment purpose. However, it also highlights the need for more precise terminology and guidance on using these methodologies.
In conclusion, assessing uncertainty is crucial in HEEs. The paper below offers a comprehensive review of the methods the industry is currently using. Nevertheless, additional work is necessary to both clarify language and provide direction on the application of these methodologies.
🚀 Is the non-opioid pain management market on the verge of a strategic shift?
Viatris’ MR-107A-02 shows 73% opioid-free recovery in herniorrhaphy, strong Phase 3 efficacy, and placebo-comparable safety.
With a $45B market at stake, the implications for commercial strategy and payer positioning are significant.
Read our full breakdown—market dynamics, clinical data, and the transformative potential of MR-107A-02.
#SyenzaNews #pharmaceuticals #HealthcareInnovation
🔍 What if we could transform the treatment landscape for chronic Hepatitis Delta Virus (HDV)?
Recent findings from Gilead’s Phase 3 MYR301 study reveal that bulevirtide therapy not only achieves remarkable virologic control during treatment but also sustains that control after therapy cessation for many patients. With a striking 90% of patients remaining undetectable post-treatment, this could signify a major breakthrough in HDV management.
Learn more about how this could reshape patient outcomes and health economics? See full article for all the insights!
#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess
💡 Is prevention really saving us money in healthcare?
In their thought-provoking article, “Can Prevention Save Money?”, Baicker and Chandra challenge the prevailing notion that preventive health measures always reduce costs. They argue that while prevention can enhance health outcomes, it often leads to increased spending upfront, and the key lies in evaluating these programs based on their cost-effectiveness instead of expecting them to save money outright.
Curious about the real financial implications of preventive care? Dive into the full analysis to uncover the nuances!
#SyenzaNews #HealthEconomics #costeffectiveness #healthcarepolicy
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
